Volume 29, Issue 171 (4-2019)
J Mazandaran Univ Med Sci 2019, 29(171): 1-10 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rezaei A, Saadat F, Safavifar F, Berahmeh A, Khorramizadeh M R. Inhibitory Effect of Coadministration of Silibinin and CpG-ODN2006 on Metastatic Characteristics (MMP-2 and TLR-9) of Hepatocarcinoma Cell Line . J Mazandaran Univ Med Sci 2019; 29 (171) :1-10
URL: http://jmums.mazums.ac.ir/article-1-11595-en.html
URL: http://jmums.mazums.ac.ir/article-1-11595-en.html
Abstract: (3298 Views)
Background and purpose: Hepatocellular carcinoma (HCC) is a most common liver malignancy and TLR9 (Toll-like receptor) is essential for CpG DNA-induced immune responses. The aim of this study was to assess the anti-metastatic effects of combined administration of silibinin and CpG-ODN2006 on human hepatocellular carcinoma HepG-2 cell line model.
Materials and methods: Inhibitory effects of various different concentrations of silibinin and CpG-ODN2006 on HepG-2 cells growth and detection of best dosages for simultaneously treatment were assessed by MTT method. Expression of MMP2 and TLR9 genes was analyzed by real- time PCR. Gelatin zymography was used to determine the activity of MMP2.
Results: Inhibitory effects of determined concentrations of silibinin (100 μM) and CpG-ODN2006 (100 nM) on HepG-2 cells growth was significant (p<0.05). Real-Time PCR showed no significant differences between Ct of the genes expression analyses.
Conclusion: Conclusion: Collectively, the data in this study supports the idea of combined silibinin-CpG administration in hepatic cancer customized therapeutic modalities. However, more investigations to assess immunomodulatory effects and safety analyses would be very informative steps in advance of randomized clinical trials.
Materials and methods: Inhibitory effects of various different concentrations of silibinin and CpG-ODN2006 on HepG-2 cells growth and detection of best dosages for simultaneously treatment were assessed by MTT method. Expression of MMP2 and TLR9 genes was analyzed by real- time PCR. Gelatin zymography was used to determine the activity of MMP2.
Results: Inhibitory effects of determined concentrations of silibinin (100 μM) and CpG-ODN2006 (100 nM) on HepG-2 cells growth was significant (p<0.05). Real-Time PCR showed no significant differences between Ct of the genes expression analyses.
Conclusion: Conclusion: Collectively, the data in this study supports the idea of combined silibinin-CpG administration in hepatic cancer customized therapeutic modalities. However, more investigations to assess immunomodulatory effects and safety analyses would be very informative steps in advance of randomized clinical trials.
Type of Study: Research(Original) |
Subject:
Hematology and Oncology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
